NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $31.54 -0.06 (-0.19%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$30.59▼$31.9850-Day Range$30.39▼$35.5352-Week Range$17.53▼$41.93Volume642,815 shsAverage Volume871,133 shsMarket Capitalization$2.43 billionP/E RatioN/ADividend YieldN/APrice Target$37.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get PTC Therapeutics alerts: Email Address PTC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.31 Rating ScoreUpside/Downside17.7% Upside$37.13 Price TargetShort InterestBearish7.74% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.86Based on 7 Articles This WeekInsider TradingSelling Shares$77,191 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.09) to ($4.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.36 out of 5 starsMedical Sector275th out of 910 stocksPharmaceutical Preparations Industry119th out of 426 stocks 3.2 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 6 buy ratings, 6 hold ratings, and 3 sell ratings.Amount of Analyst CoveragePTC Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.74% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 3.66%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 2.7 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for PTC Therapeutics this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,191.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of PTC Therapeutics is held by insiders.Read more about PTC Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.09) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PTC Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About PTC Therapeutics Stock (NASDAQ:PTCT)PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More PTCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTCT Stock News HeadlinesSeptember 7 at 4:55 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Raised to "Strong-Buy" at Baird R WSeptember 6 at 5:01 AM | americanbankingnews.comRobert W. Baird Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT)September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 29, 2024 | americanbankingnews.comAnalysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Target Price at $35.85August 28, 2024 | prnewswire.comPTC Therapeutics to Participate at Upcoming Investor ConferencesAugust 28, 2024 | americanbankingnews.comUBS Group Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT)August 27, 2024 | msn.comUBS Upgrades PTC Therapeutics (PTCT)August 13, 2024 | markets.businessinsider.comPTC Therapeutics: Balancing Strong FY24 Guidance Against Regulatory UncertaintiesSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for PTC Therapeutics on Strong Q2 Performance and Promising PipelineAugust 9, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on PTC Therapeutics (PTCT)August 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTAugust 8, 2024 | investorplace.comPTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024August 8, 2024 | prnewswire.comPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTAugust 1, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)August 1, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJuly 30, 2024 | prnewswire.comPTC Therapeutics Announces Sepiapterin NDA Submission to FDASee More Headlines Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Target$37.13 High Stock Price Target$64.00 Low Stock Price Target$25.00 Potential Upside/Downside+17.7%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-626,600,000.00 Net Margins-53.25% Pretax Margin-54.87% Return on EquityN/A Return on Assets-19.37% Debt Debt-to-Equity RatioN/A Current Ratio2.23 Quick Ratio2.17 Sales & Book Value Annual Sales$937.82 million Price / Sales2.59 Cash Flow$2.16 per share Price / Cash Flow14.58 Book Value($10.85) per share Price / Book-2.91Miscellaneous Outstanding Shares76,920,000Free Float72,479,000Market Cap$2.43 billion OptionableOptionable Beta0.64 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 51)M.D., M.S., CEO & Director Comp: $995.4kDr. Stuart W. Peltz Ph.D. (Age 64)Co-Founder, Senior Consultant & Member of Scientific Advisory Board Comp: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 78)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $145kDr. Neil Almstead Ph.D. (Age 57)Chief Technical Operations Officer Comp: $829.97kMr. Eric Pauwels (Age 63)Chief Business Officer Comp: $847.67kMr. Pierre Gravier M.S. (Age 38)Chief Financial Officer Ms. Christine Utter (Age 46)Senior VP, Chief Accounting Officer & Head of People Services Comp: $595.54kAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 63)Executive VP & Chief Legal Officer Comp: $824.09kMs. Jane BajVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsZogenixNASDAQ:ZGNXChemoCentryxNASDAQ:CCXISage TherapeuticsNASDAQ:SAGEEmergent BioSolutionsNYSE:EBSForty SevenNASDAQ:FTSVView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 94,800 shares on 8/19/2024Ownership: 0.000%Algert Global LLCBought 28,309 shares on 8/16/2024Ownership: 0.037%Creative PlanningBought 1,619 shares on 8/16/2024Ownership: 0.013%Quarry LPBought 2,500 shares on 8/16/2024Ownership: 0.007%The Manufacturers Life Insurance Company Bought 2,660 shares on 8/15/2024Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $27.56 at the start of the year. Since then, PTCT shares have increased by 14.4% and is now trading at $31.54. View the best growth stocks for 2024 here. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by $0.16. The biopharmaceutical company earned $186.70 million during the quarter, compared to analyst estimates of $192.12 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. Who are PTC Therapeutics' major shareholders? PTC Therapeutics' top institutional shareholders include Armistice Capital LLC (9.05%), Cowen AND Company LLC (4.90%), Renaissance Technologies LLC (1.07%) and Cubist Systematic Strategies LLC (0.62%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Eric Pauwels, Neil Gregory Almstead, Lee Scott Golden, Pierre Gravier, Emily Luisa Hill, Christine Marie Utter, Allan Steven Jacobson, David P Southwell, Alethia Young, Emma Reeve and Stephanie Okey. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA) and Cisco Systems (CSCO). This page (NASDAQ:PTCT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
